Combination of the Immune Modulator Dimethyl Fumarate With Intraarterial Treatment in Acute Ischemic Stroke

haojunwei5

The investigators conduct this study to investigate whether oral administration of Dimethyl Fumarate, a Food and Drug Administration-approved drug for multiple sclerosis, is safe and effective in combination with intraarterial treatment in patients with Acute Ischemic Stroke.

2021-06-01

2021-12-31

2021-12-31

Withdrawn

Early phase I

Inclusion Criteria: 1.18-80 years old 2. NIHSS score\>6 3. For the first stroke, MRI showed anterior circulation infarction 4. Patients who meet the mechanical thrombectomy treatment by MRI assessment within 24 hours Exclusion Criteria: 1. Patients receiving Alteplase thrombolysis 2. Other diseases of the central nervous system 3. There has been a neurological disability in the past (mRS score\>2) 4. Difficulty swallowing 5. Arrhythmia, atrioventricular block 6. Use of anti-tumor drugs, other immunosuppressive and immunomodulatory drugs 7. Macular edema 8. Magnetic resonance angiography shows vertebra-basilar artery obstruction 9. Hemorrhagic stroke 10. Patients who are known to have hypersensitivity to dimethyl fumarate or any excipients of this product 11. Pregnant and lactating women

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 0, 'type': 'ACTUAL'}}

2023-10-25